[go: up one dir, main page]

ES2176212T3 - Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales. - Google Patents

Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.

Info

Publication number
ES2176212T3
ES2176212T3 ES94112803T ES94112803T ES2176212T3 ES 2176212 T3 ES2176212 T3 ES 2176212T3 ES 94112803 T ES94112803 T ES 94112803T ES 94112803 T ES94112803 T ES 94112803T ES 2176212 T3 ES2176212 T3 ES 2176212T3
Authority
ES
Spain
Prior art keywords
phosphonooxymethyls
methyltiomethyls
ethers
antitumor agents
taxan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94112803T
Other languages
English (en)
Inventor
Jerzy Golik
John F Kadow
Murray A Kaplan
Wen-Sen Li
Robert K Perrone
John K Thottathil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2176212T3 publication Critical patent/ES2176212T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/48—Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the groups H01L21/18 - H01L21/326 or H10D48/04 - H10D48/07
    • H01L21/4814—Conductive parts
    • H01L21/4821—Flat leads, e.g. lead frames with or without insulating supports
    • H01L21/4839—Assembly of a flat lead with an insulating support, e.g. for TAB
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Computer Hardware Design (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Power Engineering (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS ANTITUMORALES. MAS PARTICULARMENTE, LA INVENCION SUMINISTRA NUEVOS DERIVADOS DEL TAXANO, COMPOSICIONES FARMACEUTICAS DE LOS MISMOS, Y SU USO COMO AGENTES ANTITUMORALES.
ES94112803T 1993-08-17 1994-08-16 Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales. Expired - Lifetime ES2176212T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10801593A 1993-08-17 1993-08-17
US15484093A 1993-11-24 1993-11-24
US24511994A 1994-05-17 1994-05-17

Publications (1)

Publication Number Publication Date
ES2176212T3 true ES2176212T3 (es) 2002-12-01

Family

ID=27380403

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94112803T Expired - Lifetime ES2176212T3 (es) 1993-08-17 1994-08-16 Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.

Country Status (20)

Country Link
EP (1) EP0639577B1 (es)
JP (1) JP3062986B2 (es)
KR (1) KR100249306B1 (es)
CN (2) CN1051315C (es)
AT (1) ATE217629T1 (es)
AU (2) AU694941B2 (es)
CA (1) CA2129288C (es)
CY (1) CY2295B1 (es)
CZ (1) CZ194794A3 (es)
DE (1) DE69430611T2 (es)
DK (1) DK0639577T3 (es)
ES (1) ES2176212T3 (es)
FI (1) FI113271B (es)
HU (1) HUT67742A (es)
IL (2) IL110660A0 (es)
NO (1) NO309093B1 (es)
NZ (1) NZ264240A (es)
PL (1) PL179636B1 (es)
PT (1) PT639577E (es)
RU (1) RU2128661C1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
MX9308012A (es) * 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2732340B1 (fr) * 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6593482B2 (en) * 1993-02-01 2003-07-15 Aventis Pharma S.A. Methods for preparing new taxoids and pharmaceutical compositions containing them
US6232477B1 (en) 1996-03-25 2001-05-15 Aventis Pharma S.A. Methods of preparing new taxoids and pharmaceutical compositions containing them
US6040466A (en) * 1996-03-25 2000-03-21 Rhone Poulenc Rorer Sa Taxoids, their preparation and pharmaceutical compositions containing them
US5677470A (en) * 1994-06-28 1997-10-14 Tanabe Seiyaku Co., Ltd. Baccatin derivatives and processes for preparing the same
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
JPH10508022A (ja) * 1994-10-28 1998-08-04 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク タキソイド誘導体、それらの製造、およびそれらの抗腫瘍薬としての使用
US6458976B1 (en) 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
CA2162759A1 (en) * 1994-11-17 1996-05-18 Kenji Tsujihara Baccatin derivatives and processes for preparing the same
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
ES2388248T3 (es) 1997-03-31 2012-10-11 Boston Scientific Scimed Limited Forma de dosificación que comprende taxol en forma cristalina
US6156789A (en) * 1998-03-17 2000-12-05 Rhone-Poulenc Rorer S.A. Method for treating abnormal cell proliferation in the brain
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
EP1020188A1 (en) * 1999-01-13 2000-07-19 Aventis Pharma S.A. New use of taxoid derivatives
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
CZ20013429A3 (cs) 2000-02-02 2002-04-17 Florida State University Research Foundation, Inc. Taxany substituované v poloze C7 karbonátem jako protinádorová činidla
JP2003522171A (ja) 2000-02-02 2003-07-22 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのｃ１０カーボネート置換タキサン
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2319482C2 (ru) * 2001-11-23 2008-03-20 Чугаи Сейяку Кабусики Кайся Способ идентификации противоопухолевых целевых ферментов
US7176325B2 (en) 2002-04-05 2007-02-13 Natural Pharmaceuticals, Inc. Selective acylation of secondary hydroxyl groups
US7390898B2 (en) * 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
MXPA05001390A (es) * 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
EP2276755A4 (en) 2008-03-31 2011-05-04 Univ Florida State Res Found C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
NO2719708T3 (es) 2009-11-13 2018-03-24
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
CN103906758B (zh) * 2011-08-25 2017-05-10 株式会社博纳克 配糖体化合物、硫醚的制造方法、醚、醚的制造方法、配糖体化合物的制造方法及核酸的制造方法
CN104650012A (zh) * 2013-11-22 2015-05-27 天士力控股集团有限公司 一种紫杉烷类化合物
US10377788B2 (en) 2015-04-02 2019-08-13 Bonac Corporation Method for producing glycoside compounds
CN110862410A (zh) * 2018-08-27 2020-03-06 深圳福山生物科技有限公司 三氟甲基硒化合物及其用途
JP7281564B2 (ja) 2019-06-12 2023-05-25 ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ 過酸化ジアシルを生成するためのプロセス
ES2963357T3 (es) 2019-06-12 2024-03-26 Nouryon Chemicals Int Bv Proceso para la producción de peróxidos de diacilo
WO2020249691A1 (en) 2019-06-12 2020-12-17 Nouryon Chemicals International B.V. Process for the production of diacyl peroxides
US20220306490A1 (en) * 2019-06-12 2022-09-29 Nouryon Chemicals International B.V. Method for isolating carboxylic acid from an aqueous side stream
WO2020249689A1 (en) 2019-06-12 2020-12-17 Nouryon Chemicals International B.V. Process for the production of peroxyesters

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
FR2679230B1 (fr) * 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
MX9308012A (es) * 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.

Also Published As

Publication number Publication date
IL110660A0 (en) 1994-11-11
PL304649A1 (en) 1995-02-20
CN1111637A (zh) 1995-11-15
PT639577E (pt) 2002-10-31
AU9135698A (en) 1999-01-14
CN1237580A (zh) 1999-12-08
JPH07149779A (ja) 1995-06-13
HU9402342D0 (en) 1994-10-28
IL128425A0 (en) 2000-01-31
KR950005834A (ko) 1995-03-20
AU706511B2 (en) 1999-06-17
FI113271B (fi) 2004-03-31
DE69430611D1 (de) 2002-06-20
AU7026794A (en) 1995-03-02
CY2295B1 (en) 2003-07-04
RU94029662A (ru) 1996-07-10
HUT67742A (en) 1995-04-28
FI943749L (fi) 1995-02-18
DK0639577T3 (da) 2002-08-19
KR100249306B1 (ko) 2000-04-01
CA2129288A1 (en) 1995-02-18
PL179636B1 (pl) 2000-10-31
NO943002D0 (no) 1994-08-15
FI943749A0 (fi) 1994-08-15
DE69430611T2 (de) 2002-12-19
CN1100771C (zh) 2003-02-05
RU2128661C1 (ru) 1999-04-10
ATE217629T1 (de) 2002-06-15
NZ264240A (en) 1997-10-24
CN1051315C (zh) 2000-04-12
EP0639577A1 (en) 1995-02-22
JP3062986B2 (ja) 2000-07-12
EP0639577B1 (en) 2002-05-15
AU694941B2 (en) 1998-08-06
CA2129288C (en) 2000-05-16
CZ194794A3 (en) 1995-08-16
NO309093B1 (no) 2000-12-11
NO943002L (no) 1995-02-20

Similar Documents

Publication Publication Date Title
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
DE59712873D1 (de) Halogenpyrimidinylaryl(thio)ether als pestizide
ATE193891T1 (de) Phosphonooxymethylether von taxan-derivaten
ES2085876T3 (es) Derivado de bifenilmetano, su utilizacion y composiciones farmacologicas que contienen el mismo.
ES2122043T3 (es) Nuevos derivados sustituidos del pirazol, procedimientos para su preparacion y su empleo como herbicidas.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
PA8435001A1 (es) Derivados 6,6-heterobiciclicos sustituidos.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
HN2002000300A (es) Nuevos derivados de piperazina
ATE231872T1 (de) Thiazolopyrimidinderivate
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
SE9801494D0 (sv) Novel use
AR024747A1 (es) Derivados de aminotiazoles, su preparacion y las composiciones farmaceuticas que los contienen.
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
ES2054881T3 (es) Pantetina como agente inhibidor de la fibrosis hepatica.
ES2184761T3 (es) Derivados de taxanos c10 y composiciones farmaceuticas.
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.